JP2020521490A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521490A5 JP2020521490A5 JP2019566198A JP2019566198A JP2020521490A5 JP 2020521490 A5 JP2020521490 A5 JP 2020521490A5 JP 2019566198 A JP2019566198 A JP 2019566198A JP 2019566198 A JP2019566198 A JP 2019566198A JP 2020521490 A5 JP2020521490 A5 JP 2020521490A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- seq
- binding fragment
- sequence defined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 36
- 102000036639 antigens Human genes 0.000 claims 36
- 108091007433 antigens Proteins 0.000 claims 36
- 239000012634 fragment Substances 0.000 claims 36
- 238000000034 method Methods 0.000 claims 34
- 238000004519 manufacturing process Methods 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 17
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 13
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 13
- 235000018417 cysteine Nutrition 0.000 claims 13
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 13
- 229960003067 cystine Drugs 0.000 claims 13
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 11
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 11
- 239000006143 cell culture medium Substances 0.000 claims 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000010923 batch production Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000013628 high molecular weight specie Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 230000006240 deamidation Effects 0.000 claims 1
- 238000013467 fragmentation Methods 0.000 claims 1
- 238000006062 fragmentation reaction Methods 0.000 claims 1
- 238000006317 isomerization reaction Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021141016A JP7560420B2 (ja) | 2017-05-31 | 2021-08-31 | 細胞培養方法 |
| JP2022109106A JP7406593B2 (ja) | 2017-05-31 | 2022-07-06 | 細胞培養方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1708655.4 | 2017-05-31 | ||
| GBGB1708655.4A GB201708655D0 (en) | 2017-05-31 | 2017-05-31 | Cell culture methods |
| PCT/EP2018/064102 WO2018219968A1 (en) | 2017-05-31 | 2018-05-29 | Cell culture methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021141016A Division JP7560420B2 (ja) | 2017-05-31 | 2021-08-31 | 細胞培養方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020521490A JP2020521490A (ja) | 2020-07-27 |
| JP2020521490A5 true JP2020521490A5 (enExample) | 2021-09-30 |
| JPWO2018219968A5 JPWO2018219968A5 (enExample) | 2022-06-16 |
| JP7460370B2 JP7460370B2 (ja) | 2024-04-02 |
Family
ID=59270991
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566198A Active JP7460370B2 (ja) | 2017-05-31 | 2018-05-29 | 細胞培養方法 |
| JP2021141016A Active JP7560420B2 (ja) | 2017-05-31 | 2021-08-31 | 細胞培養方法 |
| JP2022109106A Active JP7406593B2 (ja) | 2017-05-31 | 2022-07-06 | 細胞培養方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021141016A Active JP7560420B2 (ja) | 2017-05-31 | 2021-08-31 | 細胞培養方法 |
| JP2022109106A Active JP7406593B2 (ja) | 2017-05-31 | 2022-07-06 | 細胞培養方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US12077796B2 (enExample) |
| EP (2) | EP4397682A3 (enExample) |
| JP (3) | JP7460370B2 (enExample) |
| KR (3) | KR20240096888A (enExample) |
| CN (2) | CN119326882A (enExample) |
| AU (2) | AU2018276376C1 (enExample) |
| BR (1) | BR112019024390A2 (enExample) |
| CA (1) | CA3065661A1 (enExample) |
| CL (1) | CL2019003459A1 (enExample) |
| CO (1) | CO2019012871A2 (enExample) |
| EA (1) | EA201992828A1 (enExample) |
| ES (1) | ES2978394T3 (enExample) |
| GB (1) | GB201708655D0 (enExample) |
| HR (1) | HRP20240585T1 (enExample) |
| HU (1) | HUE066922T2 (enExample) |
| IL (2) | IL317828A (enExample) |
| MX (1) | MX2019014140A (enExample) |
| MY (1) | MY193535A (enExample) |
| PL (1) | PL3630946T3 (enExample) |
| RU (2) | RU2758674C2 (enExample) |
| WO (1) | WO2018219968A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201708655D0 (en) * | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
| JP2023554489A (ja) * | 2020-12-22 | 2023-12-27 | ノバルティス アーゲー | 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法 |
| GB202105424D0 (en) | 2021-04-16 | 2021-06-02 | UCB Biopharma SRL | Cell culture processes |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| EP2218775B1 (en) | 1996-08-30 | 2015-01-28 | Life Technologies Corporation | Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium |
| EP1441589B1 (en) | 2001-11-08 | 2012-05-09 | Abbott Biotherapeutics Corp. | Stable liquid pharmaceutical formulation of igg antibodies |
| EP1623019B2 (en) | 2003-05-15 | 2017-01-25 | Wyeth LLC | Restricted glucose feed for animal cell culture |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
| CN104152395B (zh) * | 2006-11-08 | 2020-03-10 | 惠氏公司 | 合理设计的细胞培养基 |
| US8030027B2 (en) * | 2008-04-29 | 2011-10-04 | St. Jude Children's Research Hospital | Method for enhancing recombinant antibody production |
| US8252557B2 (en) | 2008-10-28 | 2012-08-28 | Chugai Seiyaku Kabushiki Kaisha | Peptide-containing culture medium for culturing animal cell |
| US20110262965A1 (en) | 2010-04-23 | 2011-10-27 | Life Technologies Corporation | Cell culture medium comprising small peptides |
| CA2797140C (en) | 2010-04-26 | 2018-01-23 | Novartis Ag | Improved cell culture medium |
| CN102858954A (zh) | 2010-04-26 | 2013-01-02 | 诺瓦提斯公司 | 改进的细胞培养方法 |
| CN102653729B (zh) | 2011-03-04 | 2014-07-16 | 上海赛金生物医药有限公司 | 一种用于中国仓鼠卵巢细胞的培养基 |
| US9133493B2 (en) * | 2011-04-21 | 2015-09-15 | Amgen Inc. | Method for culturing mammalian cells to improve recombinant protein production |
| JP6265970B2 (ja) * | 2012-03-26 | 2018-01-24 | サノフイ | 安定なIgG4に基づく結合剤の製剤 |
| WO2013158275A1 (en) * | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Cell culture methods to reduce acidic species |
| US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| GB201208367D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
| JP2016513478A (ja) * | 2013-03-15 | 2016-05-16 | ジェネンテック, インコーポレイテッド | 細胞培養培地及び抗体を産生する方法 |
| KR102434588B1 (ko) | 2014-06-18 | 2022-08-22 | 메디뮨 엘엘씨 | N-아세틸시스테인을 포함하는 세포 배양 방법 및 배지 |
| KR20170100074A (ko) | 2014-12-29 | 2017-09-04 | 완롭 위롯페이싯 | 상승된 전압 및 향상된 장착 방식을 구비한 엔진 연소시스템의 산소효율 증진장치 |
| GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
| ES2967868T3 (es) | 2016-04-28 | 2024-05-06 | Merck Patent Gmbh | Método para reducir el nivel de trisulfuro en proteínas |
| GB201608323D0 (en) | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| WO2018018613A1 (zh) * | 2016-07-29 | 2018-02-01 | 广东东阳光药业有限公司 | 一种提高抗体纯度的细胞培养基和培养方法 |
| CN106222129A (zh) | 2016-07-29 | 2016-12-14 | 广东东阳光药业有限公司 | 一种提高抗体纯度的细胞培养基和培养方法 |
| GB201708655D0 (en) * | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
-
2017
- 2017-05-31 GB GBGB1708655.4A patent/GB201708655D0/en not_active Ceased
-
2018
- 2018-05-29 EP EP24164969.8A patent/EP4397682A3/en active Pending
- 2018-05-29 EP EP18743683.7A patent/EP3630946B1/en not_active Revoked
- 2018-05-29 JP JP2019566198A patent/JP7460370B2/ja active Active
- 2018-05-29 ES ES18743683T patent/ES2978394T3/es active Active
- 2018-05-29 HR HRP20240585TT patent/HRP20240585T1/hr unknown
- 2018-05-29 RU RU2019143742A patent/RU2758674C2/ru active
- 2018-05-29 CN CN202411456463.9A patent/CN119326882A/zh active Pending
- 2018-05-29 KR KR1020247019609A patent/KR20240096888A/ko active Pending
- 2018-05-29 IL IL317828A patent/IL317828A/en unknown
- 2018-05-29 KR KR1020197038895A patent/KR20200012972A/ko not_active Ceased
- 2018-05-29 CN CN201880035870.9A patent/CN110741077B/zh active Active
- 2018-05-29 MY MYPI2019006875A patent/MY193535A/en unknown
- 2018-05-29 CA CA3065661A patent/CA3065661A1/en active Pending
- 2018-05-29 KR KR1020257034169A patent/KR20250156183A/ko active Pending
- 2018-05-29 IL IL270880A patent/IL270880B2/en unknown
- 2018-05-29 AU AU2018276376A patent/AU2018276376C1/en active Active
- 2018-05-29 PL PL18743683.7T patent/PL3630946T3/pl unknown
- 2018-05-29 MX MX2019014140A patent/MX2019014140A/es unknown
- 2018-05-29 WO PCT/EP2018/064102 patent/WO2018219968A1/en not_active Ceased
- 2018-05-29 HU HUE18743683A patent/HUE066922T2/hu unknown
- 2018-05-29 BR BR112019024390-9A patent/BR112019024390A2/pt unknown
- 2018-05-29 RU RU2021128024A patent/RU2021128024A/ru unknown
- 2018-05-29 EA EA201992828A patent/EA201992828A1/ru unknown
- 2018-05-29 US US16/615,419 patent/US12077796B2/en active Active
-
2019
- 2019-11-18 CO CONC2019/0012871A patent/CO2019012871A2/es unknown
- 2019-11-26 CL CL2019003459A patent/CL2019003459A1/es unknown
-
2021
- 2021-08-31 JP JP2021141016A patent/JP7560420B2/ja active Active
-
2022
- 2022-07-06 JP JP2022109106A patent/JP7406593B2/ja active Active
-
2024
- 2024-08-23 US US18/813,117 patent/US20250051824A1/en active Pending
- 2024-11-11 AU AU2024259881A patent/AU2024259881B2/en active Active
- 2024-11-15 US US18/948,600 patent/US20250066832A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110187T1 (hr) | Multispecifične deimunizirane tvari koje vežu cd3 | |
| AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| RU2012118636A (ru) | Молекула, специфически связывающаяся с rsv | |
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| RU2013120957A (ru) | Способы лечения псориаза с использованием антагонистов il-17 | |
| JP2013056885A5 (enExample) | ||
| JP2020537520A5 (enExample) | ||
| CN115397852B (zh) | 工程化抗il-2抗体 | |
| FI2155783T4 (fi) | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| JP2019193643A (ja) | 細胞培養培地及び抗体を産生する方法 | |
| JP2020521490A5 (enExample) | ||
| JP2021503938A5 (enExample) | ||
| JP2010509931A5 (enExample) | ||
| JP2014515598A (ja) | 二重特異性三鎖抗体様分子 | |
| RU2013106217A (ru) | Гибридный белок из антитела против мнс и противовирусного цитокина | |
| HRP20240102T1 (hr) | Monoklonsko protutijelo koje antagonizira i inhibira vezanje između humanog pd-1 antigena i njegovog liganda, postupak njegove priprave i primjena | |
| HRP20231175T1 (hr) | Postupci kultiviranja stanica | |
| AR126838A1 (es) | Métodos para preparar células que expresan receptores de antígeno quiméricos | |
| JP2022122865A5 (enExample) | ||
| JP2021094022A5 (enExample) | ||
| RU2019143742A (ru) | Способы культивирования клеток | |
| JP2019509714A5 (enExample) | ||
| JPWO2018219968A5 (enExample) | ||
| US20240360225A1 (en) | METHOD FOR PRODUCING ANTI-EGFR ANTIBODY, METHOD FOR IMPROVING AFFINITY FOR Fc¿RIIIa, AND ANTI-EGFR ANTIBODY | |
| JPWO2023086817A5 (enExample) |